dc.contributor.author | Sogono, P | |
dc.contributor.author | Bressel, M | |
dc.contributor.author | David, S | |
dc.contributor.author | Shaw, M | |
dc.contributor.author | Chander, S | |
dc.contributor.author | Chu, J | |
dc.contributor.author | Plumridge, N | |
dc.contributor.author | Byrne, K | |
dc.contributor.author | Hardcastle, N | |
dc.contributor.author | Kron, T | |
dc.contributor.author | Wheeler, G | |
dc.contributor.author | Hanna, GG | |
dc.contributor.author | MacManus, M | |
dc.contributor.author | Ball, D | |
dc.contributor.author | Siva, S | |
dc.date.accessioned | 2020-12-16T23:52:59Z | |
dc.date.available | 2020-12-16T23:52:59Z | |
dc.date.issued | 2021-03-01 | |
dc.identifier | pii: S0360-3016(20)34399-6 | |
dc.identifier.citation | Sogono, P., Bressel, M., David, S., Shaw, M., Chander, S., Chu, J., Plumridge, N., Byrne, K., Hardcastle, N., Kron, T., Wheeler, G., Hanna, G. G., MacManus, M., Ball, D. & Siva, S. (2021). Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases.. Int J Radiat Oncol Biol Phys, 109 (3), pp.756-763. https://doi.org/10.1016/j.ijrobp.2020.10.011. | |
dc.identifier.issn | 0360-3016 | |
dc.identifier.uri | http://hdl.handle.net/11343/254615 | |
dc.description.abstract | PURPOSE: Fewer attendances for radiation therapy results in increased efficiency and less foot traffic within a radiation therapy department. We investigated outcomes after single-fraction (SF) stereotactic body radiation therapy (SBRT) in patients with oligometastatic disease. METHODS AND MATERIALS: Between February 2010 and June 2019, patients who received SF SBRT to 1 to 5 sites of oligometastatic disease were included in this retrospective study. The primary objective was to describe patterns of first failure after SBRT. Secondary objectives included overall survival (OS), progression-free survival (PFS), high-grade treatment-related toxicity (Common Terminology Criteria for Adverse Events grade ≥3), and freedom from systemic therapy (FFST). RESULTS: In total, 371 patients with 494 extracranial oligometastases received SF SBRT ranging from 16 Gy to 28 Gy. The most common primary malignancies were prostate (n = 107), lung (n = 63), kidney (n = 52), gastrointestinal (n = 51), and breast cancers (n = 42). The median follow-up was 3.1 years. The 1-, 3-, and 5-year OS was 93%, 69%, and 55%, respectively; PFS was 48%, 19%, and 14%, respectively; and FFST was 70%, 43%, and 35%, respectively. Twelve patients (3%) developed grade 3 to 4 treatment-related toxicity, with no grade 5 toxicity. As the first site of failure, the cumulative incidence of local failure (irrespective of other failures) at 1, 3 and 5 years was 4%, 8%, and 8%, respectively; locoregional relapse at the primary was 10%, 18%, and 18%, respectively; and distant failure was 45%, 66%, and 70%, respectively. CONCLUSIONS: SF SBRT is safe and effective, and a significant proportion of patients remain FFST for several years after therapy. This approach could be considered in resource-constrained or bundled-payment environments. Locoregional failure of the primary site is the second most common pattern of failure, suggesting a role for optimization of primary control during metastasis-directed therapy. | |
dc.language | eng | |
dc.publisher | Elsevier BV | |
dc.title | Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases. | |
dc.type | Journal Article | |
dc.identifier.doi | 10.1016/j.ijrobp.2020.10.011 | |
melbourne.affiliation.department | Sir Peter MacCallum Department of Oncology | |
melbourne.source.title | International Journal of Radiation: Oncology - Biology - Physics | |
melbourne.source.volume | 109 | |
melbourne.source.issue | 3 | |
melbourne.source.pages | 756-763 | |
melbourne.elementsid | 1469182 | |
melbourne.openaccess.url | https://europepmc.org/articles/PMC7560377?pdf=render | |
melbourne.openaccess.pmc | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560377 | |
melbourne.openaccess.status | Published version | |
melbourne.contributor.author | Kron, Tomas | |
dc.identifier.eissn | 1879-355X | |
melbourne.accessrights | Access this item via the Open Access location | |